Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.55 |
| ▸ | RAB9A | P51151 | 9/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | MLLT1 | Q03111 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17381921 | 1.00 | NPC1 (0.55) | NPC1RAB9AS1PR1FAAHUSP30 | |
| SCHEMBL17374548 | 1.00 | NPC1 (0.55) | NPC1RAB9AS1PR1FAAHUSP30 | |
| SCHEMBL17381918 | 1.00 | NPC1 (0.55) | NPC1RAB9AS1PR1FAAHUSP30 | |
| SCHEMBL17374383 | 0.87 | NPC1 (0.53) | NPC1RAB9AS1PR1FAAHUSP30 | |
| SCHEMBL21800122 | 0.87 | NPC1 (0.53) | NPC1RAB9AS1PR1FAAHUSP30 | |
| SCHEMBL17374380 | 0.87 | NPC1 (0.53) | NPC1RAB9AS1PR1FAAHUSP30 | |
| SCHEMBL17374279 | 0.87 | NPC1 (0.53) | NPC1RAB9AS1PR1FAAHUSP30 | |
| SCHEMBL21800111 | 0.87 | NPC1 (0.53) | NPC1RAB9AS1PR1FAAHUSP30 | |
| SCHEMBL17374356 | 0.87 | NPC1 (0.53) | NPC1RAB9AS1PR1FAAHUSP30 | |
| SCHEMBL17374282 | 0.87 | NPC1 (0.53) | NPC1RAB9AS1PR1FAAHUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3157917-B1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20190308960-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190022071-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2019-01-24 | — | — | US | disclosed |
| US-10174014-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180147187-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-17 | — | — | US | disclosed |
| EP-3157917-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015196071-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308960-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | NPC1 166/4885RAB9A 894/4885S1PR1 3939/4885 |
| US-10174014-B2 | Compounds, compositions, and methods for increasing CFTR activity | CFTR, ABCB4, SCNN1B | NPC1 166/4885RAB9A 894/4885S1PR1 3939/4885 |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | NPC1 166/4885RAB9A 894/4885S1PR1 3939/4885 |
| US-20190022071-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | NPC1 463/4885RAB9A 1690/4885S1PR1 1064/4885 |
| US-20180147187-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCC2, ABCB4 | NPC1 165/4885RAB9A 679/4885S1PR1 4511/4885 |
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | CFTR, ABCB4, SCNN1B | NPC1 166/4885RAB9A 894/4885S1PR1 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.